Please sign in to follow a disease.
Malignant ovarian serous tumor
MONDO:0024885An invasive malignant neoplasm that arises from the ovary and is characterized by the presence of malignant epithelial cells that, in well differentiated tumors, resemble the epithelium of the fallopian tube or, in poorly differentiated tumors, show anaplastic features and marked nuclear atypia. It includes serous adenocarcinoma and serous adenocarcinofibroma.
Also known as: malignant ovarian serous tumor, ovarian serous tumor, malignant
3028 clinical trials for this condition and its sub-types, 5 tagged with Malignant ovarian serous tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Malignant ovarian serous tumor
-
Ovarian serous adenocarcinoma 198 trials · 202 incl. sub-types
3 sub-types
-
New hope for ovarian cancer: Rina-S faces off against chemo in major trial
Disease control Recruiting nowThis large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for ovarian cancer: targeted drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for ovarian cancer: experimental drug AZD5335 faces off against standard care
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called AZD5335 against standard treatments (like chemotherapy or another targeted drug) in about 1,100 women with a tough-to-treat type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if AZD…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC